Recurrent_hepatocellular_carcinoma_after_partial_hepatectomy:_value_of_treatment_with_transcatheter_arterial_chemoembolization._The_usefulness_of_transcatheter_arterial_chemoembolization_(TACE)_of_the_hepatic_artery_was_retrospectively_evaluated_in_66_patients_who_underwent_the_procedure_for_treatment_of_hepatocellular_carcinoma_that_recurred_after_partial_hepatectomy._The_materials_infused_were_Gelfoam_sponge_or_Gelfoam_sponge_plus_Lipiodol_and_an_anticancer_agent._A_control_group_of_15_patients_with_recurrent_tumor_received_oral_anticancer_agents_alone._The_cumulative_survival_rate_for_the_TACE_group_was_88%_for_the_first_year,_57%_for_2_years,_42%_for_3_years,_and_27%_for_5_years,_whereas_that_of_the_control_group_was_80%_for_the_first_year,_27%_for_2_years,_and_18%_for_3_years._Thus,_the_prognosis_of_the_TACE_group_was_significantly_better_(p_less_than_or_equal_to_.01,_log-rank_test)_than_that_of_the_control_group._The_survival_rate_was_inversely_correlated_with_the_ratio_of_the_volume_of_the_recurrent_tumor_to_the_volume_of_the_whole_residual_liver._These_results_suggest_that_TACE_is_more_effective_than_oral_chemotherapy_for_treatment_of_hepatocellular_carcinoma_that_recurs_after_partial_hepatectomy.